Biocon inks agreement with GE Capital for equity divestment in Syngene

31 Oct 2012 Evaluate

Biocon, Asia’s premier biotechnology company, has signed an agreement with GE Equity International Mauritius, a subsidiary of GE Capital Corporation (GE Capital), which will make a primary equity investment in its research services subsidiary, Syngene International (Syngene). The Biocon Group was advised by Allegro Corporate Finance Advisors and Mundkur Law Partners.

As per the terms of the agreement, GE Capital would invest Rs 125 crore for a 7.69% equity share in Syngene. However, the transaction is subject to standard condition precedents including regulatory approvals.

Syngene registered nearly Rs 400 crore in FY12. During H1, FY13, the business continues to gain momentum with sales of nearly Rs 250 crore.

Biocon produces anti-diabetic agents like Acarbose, Pioglitazone, Repaglinides and Rosiglitazone. In the biological segment it produces Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase and Monoclonal Antibodies.

Biocon Share Price

377.80 2.55 (0.68%)
13-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1698.10
Dr. Reddys Lab 1267.60
Cipla 1330.85
Zydus Lifesciences 904.85
Lupin 2199.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×